Nettis Eustachio, Patella Vincenzo, Lombardo Carla, Detoraki Aikaterini, Macchia Luigi, Di Leo Elisabetta, Carbonara Monica, Canonica Giorgio W, Bonzano Laura
Department of Emergency and Organ Transplantation, School and Chair of Allergology and Clinical Immunology, University of Bari - Aldo Moro, Bari, Italy.
Division of Allergy and Clinical Immunology, Department of Medicine ASL Salerno, Santa Maria della Speranza" Hospital, Salerno, Italy.
Allergy. 2020 Oct;75(10):2653-2661. doi: 10.1111/all.14338. Epub 2020 May 18.
Dupilumab is an anti-IL-4Rα antibody used in the treatment of patients with moderate-to-severe atopic dermatitis (msAD). This study explored the potential benefit of dupilumab in perennial allergic rhinoconjunctivitis (PAR) and perennial allergic asthma (PAA) caused by indoor allergens in adults with msAD.
This multicentric, prospective, observational, real-life study included adult patients with msAD who had been treated with dupilumab in 16 Italian care centres. Efficacy outcomes regarding AD, PAR and PAA were collected at baseline and 16 weeks. Safety was also assessed.
We enrolled 123 patients with msAD. Between baseline and 16 weeks of treatment, the following measurements decreased statistically significantly: Eczema Area and Severity Index, SCOring AD, Patient-Oriented Eczema Measure, pruritus score, sleep score, Dermatology Life Quality Index and IgE. Dupilumab treatment in patients with comorbid PAR (n = 41) was associated with significant improvements in PAR disease control (measured using a Rhinitis Control Scoring System) and in PAR Quality of life (QoL) (measured using the Rhinoconjunctivitis QoL Questionnaire scores). In 32 patients with comorbid PAA, dupilumab significantly improved PAA control (measured using the Asthma Control Test and five-item Asthma Control Questionnaire scores) and disease-related QoL (measured using the Asthma QoL Questionnaire scores). Thirty-five patients (28.5%) developed conjunctivitis during the study period.
These results support the benefits of dupilumab for adult patients with PAR and/or PAA associated with msAD.
度普利尤单抗是一种抗白细胞介素-4受体α抗体，用于治疗中度至重度特应性皮炎（msAD）患者。本研究探讨了度普利尤单抗对患有msAD的成人因室内过敏原引起的常年性变应性鼻结膜炎（PAR）和常年性变应性哮喘（PAA）的潜在益处。
这项多中心、前瞻性、观察性、真实世界研究纳入了在16个意大利护理中心接受过度普利尤单抗治疗的成年msAD患者。在基线和16周时收集有关AD、PAR和PAA的疗效结果。同时评估安全性。
我们纳入了123例msAD患者。在治疗的基线至16周期间，以下指标有统计学显著下降：湿疹面积和严重程度指数、特应性皮炎评分、患者导向性湿疹测量、瘙痒评分、睡眠评分、皮肤病生活质量指数和IgE。合并PAR（n = 41）患者的度普利尤单抗治疗与PAR疾病控制（使用鼻炎控制评分系统测量）和PAR生活质量（QoL）（使用鼻结膜炎QoL问卷评分测量）的显著改善相关。在32例合并PAA的患者中，度普利尤单抗显著改善了PAA控制（使用哮喘控制测试和五项哮喘控制问卷评分测量）和疾病相关QoL（使用哮喘QoL问卷评分测量）。35例患者（28.5%）在研究期间发生了结膜炎。
这些结果支持度普利尤单抗对合并PAR和/或PAA的成年msAD患者有益。
